Background: Peritoneal fibrosis is a major complication leading to the loss of peritoneal function in patients undergoing peritoneal dialysis. However, the effect of catalase depletion on peritoneal fibrosis has not yet been investigated. Methods: The impact of catalase deficiency on progressive peritoneal fibrosis has been studied in homozygous acatalasemic mutant mice or control wild-type mice by intraperitoneal injection of chlorhexidine gluconate (CG) every other day for 14 days. Results: The CG injections resulted in a thicker peritoneal membrane, reflecting peritoneal fibrosis with accumulation of interstitial type I collagen, peritoneal deposition of lipid peroxidation products (4-hydroxy-2-nonenal and 4-hydroxy-2-hexenal), and an elevated level of 8-hydroxy-2′-deoxyguanosine in peritoneal fluid in both mouse groups on day 14. The extent of these changes, however, was significantly higher in acatalasemic mice than in wild-type mice. The level of catalase activity remained low in the acatalasemic peritoneum without the compensatory upregulation of glutathione peroxidase, but with an insufficient upregulation of superoxide dismutase activity in CG-injected mice. Conclusions: Acatalasemia, therefore, exacerbates oxidant tissue injury and induces the peritoneum to develop irreversible fibrosis which is the most important complication of peritoneal dialysis. This study suggests that catalase plays a crucial role in the defense against oxidant-mediated peritoneal injury in a mouse peritoneal fibrosis model.

Keywords:
Acatalasemia, mouse study, Catalase, Oxidative stress, Reactive oxygen species, Lipid peroxidation products, Peritoneal dialysis, catalase depletion
1.
Kawaguchi Y: Status of peritoneal dialysis in Japan. Perit Dial Int 2006;26:133–135.
2.
Chance B, Sies H, Boveris A: Hydroperoxide metabolism in mammalian organs. Physiol Rev 1979;59:527–605.
3.
Takahara S: Acatalasemia. Lancet 1952;2:1101–1106.
4.
Yoshio Y, Miyazaki M, Abe K, Nishino T, Furusu A, Mizuta Y, Harada T, Ozono Y, Koji T, Kohno S: TNP-470, an angiogenesis inhibitor, suppresses the progression of peritoneal fibrosis in mouse experimental model. Kidney Int 2004;66:1677–1685.
5.
Tanabe K, Maeshima Y, Ichinose K, Kitayama H, Takazawa Y, Hirokoshi K, Kinomura M, Sugiyama H, Makino H: Endostatin peptide, an inhibitor of angiogenesis, prevents the progression of peritoneal sclerosis in a mouse experimental model. Kidney Int 2007;71:227–238.
6.
Kobayashi M, Sugiyama H, Wang DH, Toda N, Maeshima Y, Yamasaki Y, Masuoka N, Yamada M, Kira S, Makino H: Catalase deficiency renders remnant kidneys more susceptible to oxidant tissue injury and renal fibrosis in mice. Kidney Int 2005;68:1018–1031.
7.
Masuoka N, Sugiyama H, Ishibashi N, Wang DH, Masuoka T, Kodama H, Nakano T: Characterization of acatalasemic erythrocytes treated with low and high dose hydrogen peroxide. Hemolysis and aggregation. J Biol Chem 2006;281:21728–21734.
8.
Wakimoto M, Masuoka N, Nakano T, Ubuka T: Determination of glutathione peroxidase activity and its contribution to hydrogen peroxide removal in erythrocytes. Acta Med Okayama 1998;52:233–237.
9.
Maruyama M, Sugiyama H, Sada K, Kobayashi M, Maeshima Y, Yamasaki Y, Makino H: Desmin as a marker of proteinuria in early stages of membranous nephropathy in elderly patients. Clin Nephrol 2007;68:73–80.
10.
Io H, Hamada C, Ro Y, Ito Y, Hirahara I, Tomino Y: Morphologic changes of peritoneum and expression of VEGF in encapsulated peritoneal sclerosis rat models. Kidney Int 2004;65:1927–1936.
11.
Ogata M: Acatalasemia. Hum Genet 1991;86:331–340.
12.
Sunami R, Sugiyama H, Wang DH, Kobayashi M, Maeshima Y, Yamasaki Y, Masuoka N, Ogawa N, Kira S, Makino H: Acatalasemia sensitizes renal tubular epithelial cells to apoptosis and exacerbates renal fibrosis after unilateral ureteral obstruction. Am J Physiol Renal Physiol 2004;286:F1030–F1038.
13.
Shostak A, Pivnik E, Gotloib L: Cultured rat mesothelial cells generate hydrogen peroxide: a new player in peritoneal defense? J Am Soc Nephrol 1996;7:2371–2378.
14.
Elgawish A, Glomb M, Friedlander M, Monnier VM: Involvement of hydrogen peroxide in collagen cross-linking by high glucose in vitro and in vivo. J Biol Chem 1996;271:12964–12971.
15.
Noh H, Kim JS, Han KH, Lee GT, Song JS, Chung SH, Jeon JS, Ha H, Lee HB: Oxidative stress during peritoneal dialysis: implications in functional and structural changes in the membrane. Kidney Int 2006;69:2022–2028.
16.
Aroeira LS, Aguilera A, Sánchez-Tomero JA, Bajo MA, del Peso G, Jiménez-Heffernan JA, Selgas R, López-Cabrera M: Epithelial to mesenchymal transition and peritoneal membrane failure in peritoneal dialysis patients: pathologic significance and potential therapeutic interventions. J Am Soc Nephrol 2007;18:2004–2013.
17.
Inagi R, Miyata T, Yamamoto T, Suzuki D, Urakami K, Saito A, van Ypersele de Strihou C, Kurokawa K: Glucose degradation product methylglyoxal enhances the production of vascular endothelial growth factor in peritoneal cells: role in the functional and morphological alterations of peritoneal membranes in peritoneal dialysis. FEBS Lett 1999;463:260–264.
18.
Tan AL, Forbes JM, Cooper ME: AGE, RAGE, and ROS in diabetic nephropathy. Semin Nephrol 2007;27:130–143.
19.
Lee HB, Yu MR, Song JS, Ha H: Reactive oxygen species amplify protein kinase C signaling in high glucose-induced fibronectin expression by human peritoneal mesothelial cells. Kidney Int 2004;65:1170–1179.
20.
Sawada T, Ishii Y, Tojimbara T, Nakajima I, Fuchinoue S, Teraoka S: The ACE inhibitor, quinapril, ameliorates peritoneal fibrosis in an encapsulating peritoneal sclerosis model in mice. Pharmacol Res 2002;46:505–510.
21.
Griendling KK, Ushio-Fukai M: Reactive oxygen species as mediators of angiotensin II signaling. Regul Pept 2000;91:21–27.
22.
Feinstein RN, Suter H, Jaroslow BN: Blood catalase polymorphism: some immunological aspects. Science 1968;159:638–640.
23.
Shaffer JB, Preston KE: Molecular analysis of an acatalasemic mouse mutant. Biochem Biophys Res Commun 1990;173:1043–1050.
24.
Wang DH, Tsutsui K, Sano K, Masuoka N, Kira S: cDNA cloning and expression of mutant catalase from the hypocatalasemic mouse: comparison with the acatalasemic mutant. Biochim Biophys Acta 2001;1522:217–220.
25.
Wang DH, Funamori Y, Ikeda S, Sato M, Kira S, Taketa K: Enhanced hepatocarcinogenesis in acatalasemic mice treated with diethylnitrosamine. Hepatol Res 1998;12:217–224.
26.
Ho YS, Xiong Y, Ma W, Spector A, Ho DS: Mice lacking catalase develop normally but show differential sensitivity to oxidant tissue injury. J Biol Chem 2004;279:32804–32812.
27.
Brezniceanu ML, Liu F, Wei CC, Tran S, Sachetelli S, Zhang SL, Guo DF, Filep JG, Ingelfinger JR, Chan JS: Catalase overexpression attenuates angiotensinogen expression and apoptosis in diabetic mice. Kidney Int 2007;71:912–923.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.